Randomized, Double-blind Placebo-controlled Clinical Study to Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of multiple-dose Kukoamine B Mesilate in Sepsis Patients
Phase of Trial: Phase I
Latest Information Update: 04 May 2018
At a glance
- Drugs Kukoamine B (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Tianjin Chase Sun Pharmaceutical
- 28 Apr 2018 Planned End Date changed from 17 Jul 2018 to 31 Dec 2018.
- 28 Apr 2018 Planned primary completion date changed from 5 Apr 2018 to 31 Dec 2018.
- 03 Aug 2017 New trial record